A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

NCT06739122 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the safety of two doses of dulaglutide (3.0 mg and 4.5 mg) in children and adolescents with type 2 diabetes.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 55 people Planned (estimated).

Who can join Ages 10–17 · all sexes

Timeline Started 2025-01 · est. completion 2027-12

Where 51 sites · Argentina, Mexico, United States

What this study is testing ClinicalTrials.gov NCT06739122 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.

Treatments tested

Dulaglutide also known as LY2189265 Drug

Administered SC

Main thing measured	Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06739122 ↗